Tango Therapeutics prices underwritten public offering of common stock and pre-funded warrants

Tango Therapeutics executed an underwriting agreement with J.P. Morgan Securities and Leerink Partners to sell 18.2 million shares of common stock and warrants to purchase 1.8 million shares. The offering is typical capital-raising activity for a biopharmaceutical company to fund operations and development.